Quality of life in patients with venous thromboembolism and atrial fibrillation treated with coumarin anticoagulants.
JSON
Marvig CL, Verhoef TI, de Boer A, Kamali F, Redekop K, Pirmohamed M, Daly AK, Manolopoulos VG, Wadelius M, Bouvy M, Maitland-van der Zee AH, EU-PACT consortium
Thromb. Res. 136 (1) 69-75 [2015-07-00; online 2015-04-25]
Little is known about the overall quality of life (QOL) in patients newly diagnosed with venous thromboembolism (VTE) and atrial fibrillation (AF). We studied QOL in patients with VTE and AF immediately after the start of anticoagulant therapy, and after three months of treatment. Furthermore we identified whether QOL was affected by age, gender and nationality. The European pharmacogenetics of anticoagulant therapy (EU-PACT) study was a multicentre, randomized controlled trial of patients aged >18years diagnosed with VTE or AF. QOL was assessed using EuroQol 5 dimensions (EQ-5D) questionnaires. The EQ-5D questionnaires were completed by 187 patients with VTE and 660 patients with AF. The QOL in patients diagnosed with VTE or AF was significantly impaired, however, during a 3months treatment period, patients experienced an improvement (p<0.05). The QOL in patients diagnosed with VTE improved with increasing age, with similar effects seen in men and women. Men and women diagnosed with AF differed in QOL (respectively 0.84 and 0.74, p<0.05), and QOL decreased with age. Comparison between countries showed significant differences in the EQ-Index score at follow-up of patients with VTE, and in both EQ-Index score and EQ-VAS of patients with AF. The QOL in patients with VTE and AF is strongly reduced directly after the start of anticoagulant treatment, but improves within 3months. Moreover, QOL is influenced by demographic and disease-specific variables. These findings provide useful information for future cost-effectiveness studies.
PubMed 25956287
DOI 10.1016/j.thromres.2015.04.026
Crossref 10.1016/j.thromres.2015.04.026
pii: S0049-3848(15)00198-X